Riga, Latvia, 2016-01-04 16:09 CET (GLOBE NEWSWIRE) --
JSC “Grindeks” announces it has received the statement of the company’s Member of the Board Vadims Rabsha on his resignation from the position of Member of the Board on his own volition starting from January 4, 2016.
Until further notice the Board of JSC “Grindeks” will consist of Chairman of the Board Juris Bundulis and Member of the Board, Commercial Director Ibraim Muhtsi.
About “Grindeks”
“Grindeks” is an international, vertically integrated pharmaceutical company. Main fields of action are research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” consists of five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 13 countries.
“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of generics included therein. Currently “Grindeks” produces 25 active pharmaceutical ingredients.
Products of the company are exported to 60 countries and its export comprises 94% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, the Netherlands, Germany, Canada, the U.S., France, Ireland and Japan.
To increase production capacity and develop infrastructure, since 2002 the company has accomplished many significant investment projects, investing more than 70 million euros over the years.
Further information: Laila Klavina Head of the Communications Department, JSC “Grindeks” Phones: (+371) 67083370, (+371) 29256012 Fax: (+371) 67083505 laila.klavina@grindeks.lv
